Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 705 of 5804
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improveme…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a cancer vaccine train the body to fight advanced tumors?
⭐️ CURE ⭐️ CompletedThe purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study
Phase: PHASE1 • Sponsor: Aston Sci. Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New hope for kids with tough cancers: Two-Drug attack on tumors
Disease control Recruiting nowThe phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and partic…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to boost CAR-T success in hard-to-treat lymphomas
Disease control TerminatedThis is a multicenter Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and an FDAapproved CAR-T product Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or l…
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New program aims to stop addiction before it starts in young families
Prevention CompletedYoung parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD). Those identified as engaging in opioid or methamphetamine misuse are at high risk for escalation…
Phase: NA • Sponsor: Chestnut Health Systems • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
Bipolar hormone therapy shows promise in stubborn prostate cancer
Disease control OngoingThis is a multi-center, open-label, phase II, single-arm trial evaluating combination of darolutamide and high testosterone doses - extreme bipolar androgen therapy (ExBAT) - in patients with metastatic castration-resistant prostate cancer (mCRPC).
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Digital diet program aims to remit diabetes in 64 patients
Disease control CompletedThe study team will study the efficacy of a high intensity medical weight loss intervention paired with a digital platform to create weight loss and induce remission of type 2 diabetes mellitus (T2DM) compared to a diabetes self-management education intervention. The digital plat…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Rectal cancer patients may avoid surgery with new Chemo-Radiation combo
Disease control CompletedThis study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated with …
Phase: PHASE2 • Sponsor: Servicio de Salud Metropolitano Sur Oriente • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Bladder cancer drug delivered directly: a new hope for BCG failures
Disease control OngoingThis study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
Phase: PHASE1, PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Smart drug targets breast cancer in the brain
Disease control OngoingThis phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitec…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control Recruiting nowThis phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New dosing schedule of immunotherapy shows promise for hard-to-treat lymphomas
Disease control CompletedThe primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Moderna's zika vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ CompletedThis clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:51 UTC
-
New antibody shows promise in shrinking MS brain lesions
Disease control OngoingPrimary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug shows promise for reversing liver damage in NASH patients
Disease control CompletedThis is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Phase: PHASE2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone or together
Disease control OngoingThis study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: * Ipilimumab * Nivolumab
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy shows promise for tough bone cancer
Disease control OngoingA phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Surgery gives new hope for hand movement after paralysis
Disease control Recruiting nowThe goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are: * Does nerve transfer improv…
Sponsor: University of British Columbia • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New schizophrenia drug KarXT shows promise in Long-Term safety trial
Disease control CompletedThis is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will rec…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 26, 2026 18:11 UTC